Poloxime
Based on 1 Customer Validation
Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 95.0%
- No. CAS: 17302-61-3
- Fòrmula: C10H13NO2
- Peso molecular:179.22
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-12045
HMN-214PLK1 Inhibitor -
HY-12134
PoloxinPLK Inhibitor -
HY-11003
GW843682XPLK Inhibitor -
HY-15158
SBE13 HydrochloridePlk1 Inhibitor -
HY-108597
TC-S 7005PLK2 Inhibitor -
HY-15159
Cyclapolin 9PLK1 Inhibitor -
HY-15160
TAK-960PLK1 Inhibitor -
HY-50877
GSK461364PLK1 Inhibitor -
HY-12137
VolasertibPLK1 Inhibitor -
HY-15155
MLN0905PLK1 Inhibitor -
HY-15828
OnvansertibPLK1 Inhibitor -
HY-15161
Ro3280PLK1 Inhibitor
Actividad biológica
Descripciòn
IC50 & Target
[1]|
PLK1 |
In Vitro
Poloxime (100 μM) inhibits phosphopeptide binding to polo-box domain (PBD) of polo-like kinase 1 (Plk1)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 17302-61-3
-
Appearance Solid
-
Peso molecular 179.22
-
Fòrmula C10H13NO2
-
Color Light yellow to yellow
-
SMILES
CC1=CC(C(C(C)C)=C/C1=N\O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (557.97 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Liu M, et al. Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors. Bioorg Med Chem Lett. 2015 Feb 1;25(3):431-4. [Content Brief]
[2]. Yin Z, et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem Biol. 2013 Feb 15;8(2):303-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.5797 mL | 27.8987 mL | 55.7973 mL | 139.4934 mL |
| 5 mM | 1.1159 mL | 5.5797 mL | 11.1595 mL | 27.8987 mL | |
| 10 mM | 0.5580 mL | 2.7899 mL | 5.5797 mL | 13.9493 mL | |
| 15 mM | 0.3720 mL | 1.8599 mL | 3.7198 mL | 9.2996 mL | |
| 20 mM | 0.2790 mL | 1.3949 mL | 2.7899 mL | 6.9747 mL | |
| 25 mM | 0.2232 mL | 1.1159 mL | 2.2319 mL | 5.5797 mL | |
| 30 mM | 0.1860 mL | 0.9300 mL | 1.8599 mL | 4.6498 mL | |
| 40 mM | 0.1395 mL | 0.6975 mL | 1.3949 mL | 3.4873 mL | |
| 50 mM | 0.1116 mL | 0.5580 mL | 1.1159 mL | 2.7899 mL | |
| 60 mM | 0.0930 mL | 0.4650 mL | 0.9300 mL | 2.3249 mL | |
| 80 mM | 0.0697 mL | 0.3487 mL | 0.6975 mL | 1.7437 mL | |
| 100 mM | 0.0558 mL | 0.2790 mL | 0.5580 mL | 1.3949 mL |
Poloxime Related Classifications
HY-77195 Related Classifications
Powered by Bioz